ホームMCPワークベンチSkills
ホームワークベンチ通知マイページ
llms.txt · MCPガイドプライバシーポリシー · 利用規約 · サポートv1.8.3
  1. ホーム
  2. /化合物

カンナビジオール

Cannabidiol

HCID 644019
反応を作成
印刷

データを補完しています。しばらくしてからページを更新すると最新の内容を表示できます

基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
部分構造検索類似構造を探す

基本情報

CAS
13956-29-1
標準SMILES
C=C(C)[C@@H]1CCC(C)=C[C@H]1c1c(O)cc(CCCCC)cc1O
InChIKey
QHMBSVQNZZTUGM-ZWKOTPCHSA-N
分子式
C21H30O2
平均分子量
314.5 g/mol
単同位体質量
314.2245802

概要

Cannabidiol is an cannabinoid that is cyclohexene which is substituted by a methyl group at position 1, a 2,6-dihydroxy-4-pentylphenyl group at position 3, and a prop-1-en-2-yl group at position 4. It has a role as an antimicrobial agent and a plant metabolite. It is a member of resorcinols, a phytocannabinoid and an olefinic compound.

名称と識別子

優先名称
Cannabidiol
IUPAC
2-[(1R,6R)-3-methyl-6-prop-1-en-2-ylcyclohex-2-en-1-yl]-5-pentylbenzene-1,3-diol
現地名
カンナビジオール
英語名
CANNABIDIOL
分子式
C21H30O2
分子量
314.46

名称と別名

cannabidiol13956-29-1(-)-Cannabidiol(-)-trans-CannabidiolEpidiolexdelta1(2)-trans-CannabidiolGWP42003-PcannabidiolumCARDIOLRX(-)-trans-2-p-Mentha-1,8-dien-3-yl-5-pentylresorcinolNanoCDBMelody Cloverstrip
名称をさらに表示
2-[(1R)-3-メチル-6β-イソプロペニル-2-シクロヘキセン-1α-イル]-5-ペンチルレソルシノール(-)-2-[(3R,4R)-p-メンタ-1,8-ジエン-3β-イル]-5-ペンチルレソルシノール(-)-カンナビジオール2-(3-メチル-6β-イソプロペニル-2-シクロヘキセン-1α-イル)-5-ペンチルレソルシノール2-[(1R,6R)-3-メチル-6-(1-メチルエテニル)-2-シクロヘキセン-1-イル]-5-ペンチル-1,3-ベンゼンジオールカンナビジオール(-)-trans-カンナビジオールカンナビジオール 溶液CBDCBD Isolatecannabidiol (CBD)CBD isolate powder2-[(1R,6R)-3-METHYL-6-(1-METHYLETHENYL)-2-CYCLOHEXEN-1-YL]-5-PENTYL-1,3-BENZENEDIOLC07578CBD crystal
CBD Oil19GBJ60SN5CHEBI:69478DTXSID00871959BTX-1204BTX-1503GWP42003GWP-42003-P

データベース識別子

CAS
13956-29-1、3556-78-3
PubChem CID
644019
DTXSID
DTXSID00871959
ChEMBL
CHEMBL190461
ChEBI
CHEBI:69478
UNII
19GBJ60SN5、QJ36T2J3TS
EC Number
689-176-3、952-348-6
Nikkaji
J10.356J

物性

構造計算による物性補完中

XLogP
6.5
極性表面積
40.5 Ų
水素結合供与体数
2
水素結合受容体数
2
回転可能結合数
6
重原子数
23
形式電荷
0
複雑度
414

実験および物理化学的性質

Chemical ClassesStimulant
DrugsDEA NFLIS-Drug Category -> Cannabinoids
LipidsPolyketides [PK] -> Aromatic polyketides [PK13] -> Other aromatic polyketides [PK1312]
LogP5.79
Dietary Ingredients · 2 件

Cannabidiol (CBD)

CBD (cannabidiol)

Human Drugs · 5 件

Breast feeding; Lactation; Milk, Human; Anticonvulsants; Cannabinoids

FDA approved drugs -> Active ingredient

EMA approved medicines: Human medicine (Orphan designations)

FDA approved drugs -> Active ingredient

Pharmaceuticals

Endocrine DisruptorsPotential endocrine disrupting compound

物理化学的性質

融点
62 · 62-63°C
比旋光度
27 · D27 -125° (0.066 g in 5 ml 95% ethanol); D18 -129° (c = 0.45 in ethanol)
沸点
2 · bp2 187-190° (bath temp 220°); bp0.001 130°
比重(密度)
440 · d440 1.040
屈折率
20 · nD20 1.5404
闪点
11 °C · 11 °C
貯蔵温度
2 · 2-8°C
溶解性
75 mM · Soluble to 75 mM in ethanol and to 75 mM in DMSO
外見
powder
色
White
主な用途
医薬品
化粧品成分の機能
皮脂抑制肌を保護する抗酸化物質スキンコンディショニング
InChI
1S/C21H30O2/c1-5-6-7-8-16-12-19(22)21(20(23)13-16)18-11-15(4)9-10-17(18)14(2)3/h11-13,17-18,22-23H,2,5-10H2,1,3-4H3/t17-,18/m0/s1
InChIKey
QHMBSVQNZZTUGM-ZWKOTPCHSA-N
LogP
6.6 · 6.600 (est)
EPAの化学物質情報
1 · 1,3-Benzenediol, 2-[(1R,6R)-3-methyl-6-(1-methylethenyl)-2-cyclohexen-1-yl]-5-pentyl- (13956-29-1)

化学的性質

化学的特性Off-White Solid

安全と法規制

安全情報は参考情報です。供給元の安全データシート(SDS)、適用法令、専門家による評価に代わるものではありません。

GHS分類

GHS Classification · 4 件

Warning

H302 (41.7%): Harmful if swallowed [Warning Acute toxicity, oral]

P203, P261, P264, P270, P271, P280, P301+P317, P304+P340, P317, P318, P330, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 36 reports by companies from 14 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

危険有害性情報

Regulatory InformationCannabidiol: Does not have an individual approval but may be used as a component in a product covered by a group standard. It is not approved for use as a chemical in its own right.
Hazard Classes and CategoriesAcute Tox. 4 (41.7%)

毒性情報

Hepatotoxicity · 1 件

In prelicensure studies, serum aminotransferase elevations arose during cannabidiol therapy for epilepsy in 34% to 47% of patients compared to 18% of controls who were receiving other anticonvulsant medications. Elevations above 3 times ULN occurred in 13% of cannabidiol treated compared to 1% on placebo. ALT and AST elevations were more frequent with higher doses and were particularly common (and sometimes delayed) in patients who were receiving valproate and clobazam. The aminotransferase elevations typically arose within the first two months of treatment and were transient, mild-to-moderate in severity, and not associated with symptoms or jaundice. There have been no convincing reports of clinically apparent liver injury with jaundice attributable to prescription forms of cannabidiol, but it has had very limited general use.

Drug Induced Liver Injury · 6 件

Drug Induced Liver Injury Rank (DILIrank 2.0)

Cannabidiol

Ambiguous-DILI-concern

3

Warnings & precautions

DOI:10.1016/j.drudis.2016.02.015

Effects During Pregnancy and Lactation◉ Summary of Use during Lactation

安全データ

wgk
1
rtecs
VH1600000
ridadr
UN 1230 3/PG 2
risk_code
11-23/24/25-39/23/24/25
hazard_code
F,T
safety_code
36/37-45-16-7

化学と産業

薬理情報

ATC Code · 2 件

N - Nervous system

QN - Nervous system

Pharmacodynamics · 1 件

Although the exact mechanism and magnitude of effects of THC and CBD are not fully understood, CBD has been shown to have analgesic, anticonvulsant, muscle relaxant, anxiolytic, neuroprotective, anti-oxidant, and anti-psychotic activity. This wide variety of effects is likely due to it's complex pharmacological mechanisms. In addition to binding to CB1 and CB2 receptors of the endocannabinoid system, there is evidence that CBD activates 5-HT1A serotonergic and TRPV1–2 vanilloid receptors, antagonizes alpha-1 adrenergic and µ-opioid receptors, inhibits synaptosomal uptake of noradrenaline, dopamine, serotonin and gaminobutyric acid and cellular uptake of anandamide, acts on mitochondria Ca2 stores, blocks low-voltage-activated (T-type) Ca2 channels, stimulates activity of the inhibitory glycine-receptor, and inhibits activity of fatty amide hydrolase (FAAH).

Mechanism of Action · 1 件

The exact mechanism of action of CBD and THC is not currently fully understood. However, it is known that CBD acts on cannabinoid (CB) receptors of the endocannabinoid system, which are found in numerous areas of the body, including the peripheral and central nervous systems, including the brain. The endocannabinoid system regulates many physiological responses of the body including pain, memory, appetite, and mood. More specifically, CB1 receptors can be found within the pain pathways of the brain and spinal cord where they may affect CBD-induced analgesia and anxiolysis, and CB2 receptors have an effect on immune cells, where they may affect CBD-induced anti-inflammatory processes. CBD has been shown to act as a negative allosteric modulator of the cannabinoid CB1 receptor, the most abundant G-Protein Coupled Receptor (GPCR) in the body. Allosteric regulation of a receptor is achieved through the modulation of the activity of a receptor on a functionally distinct site from the agonist or antagonist binding site. The negative allosteric modulatory effects of CBD are therapeutically important as direct agonists are limited by their psychomimetic effects while direct antagonists are limited by their depressant effects.

Biological Half-LifeThe CBD component of sublingual Sativex was found to have a half life (t1/2) of 1.44hr, while buccal Sativex was found to have a half life (t1/2) of 1.81hr.
Metabolism/Metabolites · 1 件

THC and CBD are metabolized in the liver by a number of cytochrome P450 isoenzymes, including CYP2C9, CYP2C19, CYP2D6 and CYP3A4. They may be stored for as long as four weeks in the fatty tissues from which they are slowly released at sub-therapeutic levels back into the blood stream and metabolized via the renal and biliary systems. The main primary metabolite of CBD is 7-hydroxy-cannabidiol.

FDA Pharmacological Classification · 6 件

19GBJ60SN5

CANNABIDIOL

Chemical Structure [CS] - Cannabinoids

Mechanisms of Action [MoA] - Cytochrome P450 2C8 Inhibitors

Mechanisms of Action [MoA] - Cytochrome P450 2C9 Inhibitors

Mechanisms of Action [MoA] - Cytochrome P450 2C19 Inhibitors

MeSH Pharmacological ClassificationDrugs used to prevent SEIZURES or reduce their severity.
Absorption, Distribution and Excretion · 3 件

Following a single buccal administration, maximum plasma concentrations of both CBD and THC typically occur within two to four hours. When administered buccally, blood levels of THC and other cannabinoids are lower compared with inhalation of smoked cannabis. The resultant concentrations in the blood are lower than those obtained by inhaling the same dose because absorption is slower, redistribution into fatty tissues is rapid and additionally some of the THC undergoes hepatic first pass metabolism to 11-OH-THC, a psycho-active metabolite. The CBD component of sublingual Sativex was found to have a Tmax of 1.63hr and a Cmax of 2.50ng/mL, while buccal Sativex was found to have a Tmax of 2.80hr and a Cmax of 3.02ng/mL.

Elimination from plasma is bi-exponential with an initial half-life of one to two hours. The terminal elimination half-lives are of the order of 24 to 36 hours or longer. Sativex is excreted in the urine and faeces.

Cannabinoids are distributed throughout the body; they are highly lipid soluble and accumulate in fatty tissue. The release of cannabinoids from fatty tissue is responsible for the prolonged terminal elimination half-life.

用途と製造

Use ClassificationPharmaceuticals

応用分野

解説カンナビジオール,大麻草に含まれるカンナビノイドの一種。鎮痛・抗痙攣(けいれん)・抗炎症・食欲増進・抗不安・免疫抑制などの薬理作用を有し、陶酔感や幻覚などは引き起こさないとされる。CBD(cannabidiol)。→テトラヒドロカンナビノール[補説]大麻草の成熟した茎や種子から抽出されるカンナビジオールは大麻取締法による規制の対象外となるため、国内でもカンナビジオールを含む健康食品や化粧品が流通している。

使用Major non-psychoactive constituent of Cannabis. Exhibits multiple bioactivities including anticonvulsant, anxiolytic and anti-inflammatory effects. The (+)-isomers were more active than the (-)-isomers.

上流・下流製品情報

下流製品

(6aR)-3-ペンチル-6,6,9-トリメチル-6aβ,7,10,10aα-テトラヒドロ-6H-ジベンゾ[b,d]ピラン-1-オール

補足説明

定義本品は、次の化学式で表される有機化合物である。

定義ChEBI: An cannabinoid that is cyclohexene which is substituted by a methyl group at position 1, a 2,6-dihydroxy-4-pentylphenyl group at position 3, and a prop-1-en-2-yl group at position 4.

関連反応

5 件
反応記録を作成
HRID 426094 の反応式
HRID 426094反応物として
HRID 426096 の反応式
HRID 426096反応物として
HRID 2067148 の反応式
HRID 2067148反応物として
HRID 2243453 の反応式
HRID 2243453反応物として
HRID 2243455 の反応式
HRID 2243455反応物として

化合物ノート

このページの内容基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート